Pre-made Belimumab benchmark antibody ( Whole mAb, anti-TNFSF13B therapeutic antibody, Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Belimumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States, Canada, and the European Union to treat systemic lupus erythematosus (SLE).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-056-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Belimumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody
INN Name	Belimumab
Target	TNFSF13B
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE
99% SI Structure	None
95-98% SI Structure	6erx:HI:DE:QR:MN:FG:OP
Year Proposed	2003
Year Recommended	2004
Companies	Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology
Conditions Approved	Systemic lupus erythematosus;Lupus nephritis
Conditions Active	Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease
Conditions Discontinued	Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome
Development Tech	CAT Phage Display